英语翻译Study at Howard University and Other Institutions Leads

英语翻译
Study at Howard University and Other Institutions Leads to Breakthrough in Treatment of Sickle Cell Anemia
WASHINGTON -- Clinical trials conducted at Howard University College of Medicine and 12 other medical institutions across the nation have discovered a treatment that dramatically reduces pain,inflammation and hospitalization time and eases other symptoms in young children suffering from sickle cell anemia .
Doctors and medical clinicians in a four-year study found that using the drug hydroxycarbamide (also called hydroxyurea) in very young children with sickle cell anemia was safe and markedly reduced episodes of pain and other problems.Hydroxycarbamide has been used in adults for several decades for a variety of cancer treatments and is approved for use in adults with sickle cell anemia.
The findings,which will be published in this week’s edition of The Lancet,the world’s leading medical journal,suggest that use of hydroxycarbamide should now be the standard of care for all children with sickle cell disease.
Dr.Sohail Rana,professor of pediatrics in the Department of Pediatrics at Howard University College of Medicine and director of pediatric hematology at Howard University Hospital,was one of the investigators on the study.
“This is a significant breakthrough in the treatment of this disease,particularly for our very young patients,” Rana said.“To be able to dramatically diminish the pain that these young children suffer because of this disease is truly an important step forward.We hope all clinicians will now adopt this treatment for their patients.”
Howard was one of the leading partners in the study,which was named BABY HUG trial.The study continues to observe children for long term benefits.
Also participating in the study were Children’s National Medical Center in Washington,Johns Hopkins University School of Medicine in Baltimore,St.Jude Children's Research Hospital in Memphis,SUNY Downstate Medical Center,University of Mississippi Medical Center,St.,Duke University Medical Center,University of Texas Southwestern Medical Center at Dallas,Medical University of South Carolina,University of Miami,Emory University School of Medicine,Children’s Hospital of Michigan,University of Alabama at Birmingham,Medical College of Georgia,the National Heart,Lung and Blood Institute and the Clinical Trials & Surveys Corporation.
In sickle cell anemia patients,the red blood cells develop abnormal shapes and are unable to pass through small blood vessels and cause blockage.These cells also break down faster than normal blood cells,leading to anemia.Complications include severe pain,stroke,damage to different organs of body and premature death.

在镰刀电池贫血的处理的霍华德大学和断缺方面的其他机构引线的研究
华盛顿－－临床实验在医学的霍华德大学学院引导了,而且其他 12个医疗的机构在全国各地已经发现一个戏剧地减少痛苦、怒火和住院治疗时间而且在受苦于镰刀电池贫血的年轻的孩子中趋疲其他症状的处理.
四个年度研究的医生和医疗的临床医生发现以镰刀电池贫血在非常年轻的孩子中使用药物 hydroxycarbamide（也被称为 hydroxyurea）是保险柜而且显着地减少痛苦和其他问题的插曲.Hydroxycarbamide 已经为多种癌处理在成人中被用好几十年而且以镰刀 c 在成人中为使用被核准